24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
MEGESLIEVA 40 MG is an Syrup medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | MEGESLIEVA 40 MG |
|---|---|
| Composition | Megestrol Acetate Oral Suspension USP 40 mg/ml |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Syrup |
| Packaging | Single Bottle Per Box |
| Country of Origin | India |
MEGESLIEVA 40 MG (Megestrol Acetate Oral Suspension USP 40 mg/ml) is a widely used Syrup medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
MEGESLIEVA 40 MG (Megestrol Acetate Oral Suspension USP 40 mg/mL) is a prescription medicine containing Megestrol Acetate 40 mg/mL, a synthetic progestin (progesterone derivative) used in the management of certain cancers and conditions associated with severe weight loss and loss of appetite. It belongs to the Hormonal Therapy class of medicines and is commonly prescribed under the supervision of an oncologist or other qualified healthcare professional.
Megestrol Acetate works by influencing hormone-sensitive tissues and helping regulate appetite. In oncology, it is used in selected hormone-responsive cancers, while it is also widely prescribed to stimulate appetite and promote weight gain in patients experiencing cancer-related cachexia or other chronic illnesses associated with significant weight loss.
MEGESLIEVA 40 MG Oral Suspension is commonly prescribed for the treatment of advanced breast cancer, advanced endometrial (uterine) cancer, cancer-related anorexia, cachexia (weight loss syndrome), and appetite loss in selected patients.
The oral suspension formulation is particularly suitable for patients who have difficulty swallowing tablets or capsules, providing convenient administration and accurate dose adjustment.
MEGESLIEVA 40 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, MEGESLIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Megestrol Acetate therapy should undergo regular medical evaluations to monitor treatment response and overall health.
MEGESLIEVA 40 MG (Megestrol Acetate Oral Suspension USP 40 mg/mL) is primarily used in the treatment and supportive management of specific medical conditions.
Used as hormonal therapy in selected patients with hormone-responsive breast cancer.
May be prescribed for the treatment of advanced or recurrent endometrial carcinoma.
Helps improve appetite and promote weight gain in cancer patients experiencing cachexia.
Used to manage loss of appetite associated with chronic illnesses.
Supports nutritional recovery in patients with unintended weight loss.
Provides nutritional and symptomatic support during cancer treatment.
Acts as part of hormone-based treatment strategies in selected cancers.
Megestrol Acetate belongs to a class of medicines known as Progestins.
MEGESLIEVA works by:
This dual mechanism supports both hormonal cancer treatment and nutritional management.
Like all medicines, MEGESLIEVA 40 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
A noticeable increase in appetite is common during treatment.
Weight gain is one of the expected effects of therapy.
Some patients may experience mild nausea.
Swelling of the hands, feet, or ankles may occur.
Blood pressure may increase in some individuals.
Weakness or tiredness may be reported.
Some patients may experience changes in mood.
Blood glucose levels may increase, particularly in patients with diabetes.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of MEGESLIEVA 40 MG (Megestrol Acetate Oral Suspension USP 40 mg/mL) should always be determined by a qualified healthcare professional.
The prescribed dose depends on the condition being treated.
Dosage may vary for appetite stimulation, weight gain, or cancer therapy.
General health and nutritional status influence treatment planning.
The dosage may be adjusted based on clinical response.
Concurrent medicines may influence treatment decisions.
Before starting treatment, inform your doctor if you have:
Patients receiving Megestrol Acetate therapy may require:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Pregnant women should not use this medicine unless specifically advised by a healthcare professional.
It is used for advanced breast cancer, advanced endometrial cancer, appetite stimulation, cancer-related cachexia, and weight loss associated with chronic illness.
Megestrol Acetate is a synthetic progestin used for hormonal therapy and appetite stimulation.
No. It is a hormonal therapy medicine, not a traditional chemotherapy drug.
Yes. One of its primary clinical uses is to improve appetite and promote weight gain.
Yes. Shake the bottle well before each dose to ensure uniform distribution of the medicine.
Patients with diabetes should use it only under medical supervision, as it may increase blood sugar levels.
Yes. Routine monitoring of body weight, blood pressure, blood sugar, and overall health is recommended.
Yes. This medicine should only be used according to the advice of a qualified healthcare professional.